Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)

The summary for the Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required): Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). Based on the proposed research, applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). This is a re-issuance of PAR-23-284. The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. The research supported through this program must be translational and be based on human biology research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must reach a translational human endpoint within the project period of the grant.

Federal Grant Title:	Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-28-022
Type of Funding:	Grant
CFDA Numbers:	93.121, 93.395
CFDA Descriptions:	Information not provided
Current Application Deadline:	September 25th, 2029
Original Application Deadline:	September 25th, 2029
Posted Date:	October 14th, 2026
Creation Date:	October 14th, 2026
Archive Date:	November 25th, 2029
Total Program Funding:	$1,400,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:	10
Cost Sharing or Matching:	No
Last Updated:	October 14th, 2026

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grant Announcement Contact: Translational Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI)
[email protected]
Division of Cancer Treatment and Diagnosis/National Cancer Institute
Similar Government Grants: • Collaborative Program Grant for Interdisciplinary Teams (RM1 Clinical Trial Optional); • Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Tr...; • HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required); • NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health ...; • Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R0...; • Epidemiological and Behavioral Research in Oral Health; • Metagenomic Analyses of the Oral Microbiome; • Phase Iii Clinical Trials in Oral Infectious Diseases
More Grants from the National Institutes of Health: • Specialized Alcohol Research Centers (P50 Clinical trial Optional); • Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Bio...; • Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) ...; • Assessing the Feasibility of Incorporating Mechanisms in Multi-site Clinical Trials of Min...; • Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (R...